UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma has maintained a Buy rating on Teva Pharmaceutical Industries (NYSE:TEVA) and raised the price target from $24 to $26.
September 03, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Ashwani Verma has maintained a Buy rating on Teva Pharmaceutical Industries and increased the price target from $24 to $26, indicating a positive outlook.
The increase in the price target from $24 to $26 by UBS suggests a positive outlook for Teva's stock, likely leading to a short-term price increase. The Buy rating reaffirms confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100